Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen?

References

• Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005;103:2241–51
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747–52
   PubMed Web of Science ®Google Scholar
• Howell SJ. Advances in the treatment of luminal breast cancer. Curr Opin Obstet Gynecol 2013;25:49–54
   PubMed Web of Science ®Google Scholar
• Preece PE, Wood RA, Mackie CR, Cuschieri A. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed) 1982;284:869–70
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2013;31:2942–62
   PubMed Web of Science ®Google Scholar
• Chien AJ, Duralde E, Hwang R, et al. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat 2015;153:173–81
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Climacteric 2014;17557–63
   Web of Science ®Google Scholar
• Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008;13:222–31
   PubMed Web of Science ®Google Scholar
• Chin SN, Trinkaus M, Simmons C, et al. Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer 2009;9:108–17
   PubMed Web of Science ®Google Scholar
• Sestak I, Cuzick J. Update on breast cancer risk prediction and prevention. Curr Opin Obstet Gynecol 2015;27:92–7
   PubMed Web of Science ®Google Scholar
• Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med 2015;5:50–66
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Committee Opinion Number 659. Obstet Gynecol 2016;127:e93–6
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Balcueva EP, Liu H, et al. A Phase III randomized, double blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA. J Support Oncol 2011;9:105–12
   PubMedGoogle Scholar
• Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36). Rev Bras Reumatol 1999;39:143–50
   Google Scholar
• Bartula I, Sherman KA. The Female Sexual Functioning Index (FSFI): evaluation of acceptability, reliability, and validity in women with breast cancer. Support Care Cancer 2015;23:2633–41
   PubMed Web of Science ®Google Scholar
• Conover WJ. Practical Nonparametric Statistics, 3rd edn. New York: John Wiley & Sons Inc.,1999
   Google Scholar
• Mimoun S, Wylie K. Female sexual dysfunctions: definitions and classification. Maturitas 2009;63:116–18
   PubMed Web of Science ®Google Scholar
• Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178–80
   PubMed Web of Science ®Google Scholar
• Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259–63
   PubMed Web of Science ®Google Scholar
• Lorizio W, Wu AH, Beattie MS, et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 2012;132:1107–18
   PubMed Web of Science ®Google Scholar
• Greenblum CA, Rowe MA, Neff DF, Greenblum JS. Midlife women: symptoms associated with menopausal transition and early postmenopause and quality of life. Menopause 2013;20:22–7
   PubMed Web of Science ®Google Scholar
• Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000;92:1054–64
   PubMed Web of Science ®Google Scholar
• Stika CS. Atrophic vaginitis. Dermatol Ther 2010;23:514–22
   PubMed Web of Science ®Google Scholar
• Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med 2011;8:549–59
   PubMed Web of Science ®Google Scholar
• Bennett N, Incrocci L, Baldwin D, et al. Cancer, benign gynecology, and sexual function – issues and answers. J Sex Med 2016;13:519–37
   PubMed Web of Science ®Google Scholar
• Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003;45:29–38
   PubMed Web of Science ®Google Scholar
• Kornblith AB, Ligibel J. Psychosocial and sexual functioning of survivors of breast cancer. Semin Oncol 2003;30:799–813
   PubMed Web of Science ®Google Scholar
• Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 1998;152:396–411
   PubMedGoogle Scholar
• Fernandes T, Costa-Paiva LH, Pinto-Neto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. J Sex Med 2014;11:1262–70
   PubMed Web of Science ®Google Scholar